Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/

Joan Lau, Ph.D. - Board Member, Rockwell Medical (Nasdaq:RMTI) (Photo: Business Wire)

Joan Lau, Ph.D. - Board Member, Rockwell Medical (Nasdaq:RMTI) (Photo: Business Wire)

"We are pleased to welcome Joan to Rockwell Medical's board of directors," said Robert S. Radie, Chairman of the Board of Directors at Rockwell Medical. "Joan has founded, led, and scaled a number of biotechnology companies throughout her career, possessing a significant amount of business development, operational, and M&A expertise. Additionally, her experience as a public company board member will be valuable to Rockwell Medical as the Company continues to grow its customer base and portfolio of products, to serve the needs of dialysis clinics and the patients they serve, and to position Rockwell to achieve its goal of increasing shareholder value.”

Dr. Lau has more than 20 years’ experience in executive leadership of R&D focused biopharma as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies. Currently, Dr. Lau is CEO of Spirovant, where she is responsible for the strategic direction and growth of the gene therapy company. Previously, Dr. Lau co-founded and was Managing Partner of Militia Hill Ventures, which focuses on building and growing high quality life sciences companies. Dr. Lau led several biotech companies including Azelon Pharmaceuticals as President and CEO; Locus Pharmaceuticals; and Immunome as COO. Additionally, she served as a director of Renovacor (NYSE:RCOR) until its acquisition by Rocket Pharmaceuticals and began her biopharmaceutical career at Merck Research Laboratories.

Engaged in the Philadelphia community, Dr. Lau serves on the Boards of Trustees for the University of Pennsylvania, Brandywine Realty Trust (NYSE:BDN), and the Philadelphia Orchestra. Dr. Lau earned a MBA from the Wharton School of Business and a BSE in Bioengineering, both at the University of Pennsylvania, and a Ph.D. in Neuroscience from the University of Cincinnati College of Medicine.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and intends to become the leading global supplier of hemodialysis concentrates. Certified as a Great Place to Work® in 2023, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.RockwellMed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” "work to," "drive towards," “focused on,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2022, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Contacts

Heather R. Hunter

SVP, Chief Corporate Affairs Officer

(248) 432-1362

IR@RockwellMed.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.